for cardiac differentiation. 10 It also has been shown that overexpression of Nkx2.5 induced cardiomyogenesis in this system, suggesting that its activity is sufficient to drive differentiation under certain conditions. 11 The role of Nkx factors during heart development has been examined on a finer scale. Analysis of the role of Nkx2.5 in the second heart field identified a negative feedback loop in which Nkx2.5 inhibits Bmp2/Smad1 signaling, ultimately controlling the specification and proliferation of progenitors. 12 In zebrafish, morpholino-mediated inhibition of nkx2.5 and nkx2.7 expression resulted in the formation of an excess number of atrial cardiomyocytes paralleled by a decrease in the number of ventricular cardiomyocytes, suggesting that Nkx genes differentially regulate distinct progenitor populations within the developing heart. 13 Nkx2.5 regulates many targets via direct interactions with other cardiomyogenic transcription factors, including GATA4, Tbx5, and MEF2C. [14] [15] [16] These interactions confer specificity and modulate Nkx2.5 activity. Although Nkx2.5 usually acts as a transcriptional activator, it can repress target gene expression in the context of particular regulatory complexes. Specifically, cooperation of Nkx2.5 with Tbx5 promotes expression of atrial natriuretic factor, whereas interaction with Tbx2 is repressive. 15, 17, 18 This differential partnership results in repression of atrial natriuretic factor expression and the formation of chamber myocardium in Tbx2-expressing regions of the developing heart. 18 These findings highlight the importance of cofactor interactions for the regulation of Nkx2.5 activity.
Cardiomyogenesis is also regulated by the action of signaling molecules derived from surrounding tissue structures. In particular, the Wnt signaling cascade plays opposing roles at different stages of cardiomyogenesis. 19 Wnt signaling mediated by Wnt3a is important for the induction of mesoderm both in vivo and in mESCs. 20, 21 A lack of canonical Wnt signaling resulted in the loss of mesoderm posterior expression, which is perhaps the earliest marker of cardiogenic mesoderm. 21, 22 Conversely, specification of cardiac progenitor cells from mesoderm posterior +ve cells is potentiated by the Wnt inhibitor Dickkopf1 (Dkk1), indicating that Wnt signaling is inhibitory at this later stage. 23, 24 Consistent with this, activation of Wnt/β-catenin signaling in differentiating mESCs at later stages resulted in reduced cardiomyogenesis. 25, 26 Although the multiphasic and multifunctional nature of Wnt signaling has been studied extensively, 19 the molecular mechanisms whereby Wnts exert these differential effects on cardiomyogenesis remain largely undefined.
To gain insight into the complex function of Nkx2.5, we have undertaken a proteomic screen to identify novel cofactors in the context of cardiomyogenesis. The β-isoform of protein phosphatase 1 (PP1β, also known as PP1δ) and its regulatory subunit myosin phosphatase targeting subunit 1 (Mypt1), 2 subunits of the myosin phosphatase (MP) enzyme complex, were identified as putative cofactors of Nkx2.5 and validated by coimmunoprecipitation. Together with myosin light chain kinase, MP modulates the balance of phosphorylation of the regulatory light chain of myosin II, thereby regulating muscle contraction. 27 We show that MP induces exclusion of Nkx2.5 from the nucleus and inhibits its transcriptional activity. This occurs downstream of Wnt signaling and is modulated by Rho-associated protein kinase (ROCK)-mediated phosphorylation of Mypt1. Inhibition of cardiomyogenesis by Wnt3a 26 is accompanied by increased nuclear exclusion of endogenous Nkx2.5 and is rescued by knockdown of Mypt1. Our findings suggest a novel mechanism whereby Wnt3a inhibits the terminal stages of cardiomyogenesis in stem cells.
Methods
Protocols are described in detail in the Online Data Supplement. mESCs were maintained as previously described. 28 Briefly, differentiation was induced by embryoid body (EB) formation for 5 days, followed by 2 days of adherent culture. All transfections were performed in human embryonic kidney-293 cells or P19 cells using Fugene (Roche) or Lipofectamine2000 (Life Technologies). Luciferase assays were performed using the Dual-Luciferase reporter assay system (Promega). Stable cell lines were generated in mESCs using Expression Arrest GIPZ lentiviral short hairpin (sh) RNAmir particles targeted to Mypt1, along with a nonsilencing control (Thermo Fisher Scientific). Images were captured using a Zeiss Laser Scanning Microscope 510 Meta microscope or a Zeiss Laser Scanning Microscope 710 Multiphoton microscope equipped with Zen Software (Zeiss) and subsequently edited in Canvas11. Gene expression analysis was performed by quantitative polymerase chain reaction as described previously. 29 Expression data were normalized to β-actin, and averages±SEM were expressed as fold-change relative to vehicle treatment.
Results

PP1β and Mypt1 Interact With Nkx2.5 and Inhibit Its Transcriptional Activity
To identify novel interacting partners of Nkx2.5 during cardiomyogenesis in stem cells, we performed a proteomic screen using affinity purification of Nkx2.5. P19 stable cell lines were generated to overexpress phosphoglycerate kinase-Nkx2.5TAP (tandem affinity purification) or phosphoglycerate kinase-TAP as a control. These cell lines, termed P19[Nkx2.5TAP] and P19[TAP], respectively, were differentiated into cardiomyocytes, and protein was harvested on day 6. Lysates were subjected to immunoprecipitation and subsequently analyzed by mass spectrometry. Using this proteomic screen technique, we identified PP1β and Mypt1 as putative binding partners of Nkx2.5 (Online Table I ). Both PP1β and Mypt1 are subunits of the MP enzyme complex. Sequence analysis of the 3 unique peptides identified for Mypt1 revealed that only 1 of these contained sequences that were also found in Mypt2, indicating that Mypt1 is the major isoform interacting with Nkx2.5.
We validated this interaction by coimmunoprecipitation experiments, in which Nkx2.5-Flag was transiently coexpressed with human influenza hemagglutinin-PP1 (HA-PP1)-β and myc-Mypt1 in human embryonic kidney-293 cells. We immunoprecipitated each subunit with antibodies specific to Flag, HA, or myc epitopes and detected the presence of interacting proteins by Western blotting. Both HA-PP1β and myc-Mypt1 coimmunoprecipitated with Flag-Nkx2.5, using an anti-Flag Figure 1A ). Reciprocal immunoprecipitations of HA-PP1β or myc-Mypt1 also coimmunoprecipitated Flag-Nkx2.5. Therefore, we have identified PP1β and Mypt1 as novel interacting partners of Nkx2.5.
To understand the implications of the interaction between Nkx2.5 and MP, we sought to examine its effect on Nkx2.5 transcriptional activity using an atrial natriuretic factorluciferase reporter. 30 Although Nkx2.5 was able to activate this reporter when transfected alone, cotransfection with HA-PP1β and myc-Mypt1 resulted in significant inhibition of reporter activation, indicating that this interaction is inhibitory to Nkx2.5-dependent transcription ( Figure 1B ). Catalytic PP1 subunits can interact with many different regulatory subunits. Therefore, we sought to ascertain whether the inhibition of Nkx2.5 was specific to MP or whether other PP1 regulatory subunits could regulate Nkx2.5. We substituted nuclear inhibitor of protein phosphatase-1 (NIPP1), the nuclear targeting subunit of PP1 31 for Mypt1, which resulted in a loss of inhibition of Nkx2.5 activity, indicating that the Mypt1 subunit is specifically required ( Figure 1B) . Interestingly, cotransfection of Nkx2.5 with HA-PP1β and both myc-Mypt1 and myc-nuclear inhibitor of protein phosphatase-1 (NIPP1) resulted in a loss of inhibition, suggesting that competition from other targeting subunits may block the association of MP subunits and its inhibitory effect on Nkx2.5.
Interaction With MP Results in Exclusion of Nkx2.5 From the Nucleus
MP dephosphorylates myosin and, as such, the enzyme complex is localized primarily in the cytoplasm. Given that Nkx2.5 is a nuclear transcription factor, we sought to determine the subcellular location of the Nkx2.5/MP interaction. Flag-Nkx2.5 was transfected with and without the MP subunits, and its subcellular localization was visualized by immunofluorescence. When transfected alone, Flag-Nkx2.5 was localized almost exclusively to the nucleus (Figure 2A and 2B). However, when coexpressed with MP, Nkx2.5 was redistributed to the cytoplasm in a perinuclear pattern ( Figure  2A ). Quantification confirmed that >60% of coexpressing cells exhibited a perinuclear distribution of Nkx2.5 ( Figure  2B ). In agreement with our reporter assays, the redistribution of Nkx2.5 did not occur in the presence of NIPP-1 ( Figure   Figure 1 . Protein phosphatase 1 (PP1) β and myosin phosphatase targeting subunit 1 (Mypt1) interact with Nkx2.5 and inhibit its transcriptional activity. A, Human embryonic kidney (HEK)-293 cells were transiently transfected with Flag-Nkx2.5, HA-PP1β, and myc-Mypt1. Total protein was harvested and immunoprecipitated with antibodies specific for Flag, HA, and myc or with mouse IgG as a control. Immunoprecipitated lysates and input (30 µg/0.02% of input) fractions were analyzed by Western blotting with the antibodies indicated. B, P19 cells were transiently transfected with the plasmids indicated or with empty vector, along with the atrial natriuretic factor (ANF)luciferase reporter and Simian virus40-Renilla as an internal control. Firefly luciferase activity was normalized to Renilla luciferase, and reporter activation was quantified as a percentage of the treatment resulting in maximum activation of the reporter. Statistical significance was calculated using ANOVA with a Dunnett post hoc test (n=4-7;**P<0.01; ***P<0.001).
Figure 2. Coexpression with myosin phosphatase (MP) results
in exclusion of Nkx2.5 from the nucleus. P19 cells were transiently transfected with the plasmids indicated and fixed 1 day later for analysis of subcellular localization. A, Fixed cells were labeled with antibodies specific to Nkx2.5 and myc-tag as well as with Hoechst dye to detect nuclei. Scale bar=10 µm. B, Subcellular localization of Nkx2.5 was quantified by imaging 10 fields in 3 independent experiments. An average of 142 cells was quantified per treatment (n=3; *P<0.05). January 18, 2013 2A and 2B). Interestingly, treatment with leptomycin B, an inhibitor of CRM1-dependent nuclear export, prevented nuclear exclusion of Nkx2.5 in the presence of MP, indicating that Nkx2.5 is exported from the nucleus via this system. Finally, coexpression with MP did not result in an altered subcellular distribution of GATA4, suggesting that this is not a regulatory mechanism affecting all cardiomyogenic transcription factors (Figure 2A ).
MP-Induced Nuclear Exclusion of Nkx2.5 Is Modulated by Phosphorylation of Mypt1
Although MP is primarily localized to the cytoplasm, phosphorylation of Mypt1 at Thr853 by ROCK causes a redistribution of the MP complex to the perinuclear region and the nucleus. 32 In addition, this phosphorylation event inhibits PP1 activity >100-fold. 33, 34 The perinuclear localization of Nkx2.5 indicated that it might interact with this phosphorylated form of MP. Colabeling with antibodies against Nkx2.5 and pMypt1T853 identified colocalization of Nkx2.5 with pMypt1T853 in the perinuclear region of cotransfected cells ( Figure 3A ). To determine whether modulation of Mypt1 phosphorylation could affect the subcellular localization of Nkx2.5, cells cotransfected with Flag-Nkx2.5 and the MP subunits were treated with the ROCK inhibitor y-27632. Consistent with previous reports, this resulted in a significant decrease (≈30%) in the levels of pMypt1 relative to total Mypt1 ( Figure 3B and 3C). 33 Redistribution of Nkx2.5 to the perinuclear region in response to coexpression with MP was significantly attenuated in the presence of y-27632 (≈40%) relative to untreated control cultures ( Figure 3D-3F ). However, treatment with y-27632 did not completely abrogate phosphorylation of Mypt1, and there remained some pMypt1T853-positive cells in which Nkx2.5 accumulated in the perinuclear region ( Figure 3F ). Interestingly, we observed a perinuclear accumulation of the myc-labeled Mypt1 in Figure 3E , indicating that in at least some cells most of the Mypt1 is phosphorylated.
Thr853 and a Nuclear Export Signal in Mypt1 Are Required for Nuclear Exclusion of Nkx2.5
To determine whether phosphorylation of Mypt1 at T853 is critical for Nkx2.5 nuclear export, we mutated T853 to alanine (Mypt1T853A) to generate a phospho-deficient form of MP and examined its ability to support Nkx2.5 exclusion. Coexpression with HA-PP1 and myc-Mypt1T853A resulted in a significant loss (>60%) of nuclear exclusion of Flag-Nkx2.5 relative to coexpression with wild-type MP, supporting the requirement of Mypt1 phosphorylation for this process ( Figure 4A and 4C). We also generated a phosphomimetic Mypt1 mutant (Mypt1T853E), although this mutant did not exclude Nkx2.5 more efficiently than wild-type Mypt1 (data not shown).
The ability of Leptomycin B to inhibit MP-induced nuclear exclusion of Nkx2.5 ( Figure 2A ) indicated that this process is mediated by chromosome region maintenance 1. We used NetNES1.1 to search for leucine-rich nuclear export signal (NES) sequences in the MP subunits and Nkx2.5. Although neither Nkx2.5 nor PP1β contained putative NES signals, 2 leucine residues near the C-terminus of Mypt1 (962 and 964 in the human sequence) were predicted to form NES. 35 We mutated these residues to alanine (Mypt1ΔNES) and examined the subcellular localization of Mypt1 and Nkx2.5.
Quantification of myc +ve nuclei revealed that whereas cultures expressing wild-type Mypt1 exhibited nuclear myc staining in ≈40% of cells, almost 80% of cells expressing Mypt1ΔNES were positive for nuclear myc ( Figure 4B and 4D) . Strikingly, coexpression with HA-PP1 and myc-Mypt1ΔNES resulted in a drastic (>80%) loss of MP-induced nuclear exclusion of Nkx2.5 ( Figure 4B and 4E), indicating that chromosome region maintenance 1-mediated nuclear export of Nkx2.5 occurs in an Mypt1-NES-dependent fashion. These data suggest a mechanism whereby phosphorylation of Mypt1 by ROCK results in translocation of MP to the nucleus, where it interacts with Nkx2.5. The complex is then exported to the perinuclear region via the Mypt1 NES.
The Wnt Inhibitor Dkk1 Blocks MP-Dependent Redistribution of Nkx2.5
ROCK-mediated phosphorylation of Mypt1, and subsequent nuclear exclusion of Nkx2.5, might be regulated via a signaling cascade that is inhibitory toward cardiomyogenesis. Wnt3a is a good candidate in this instance because it is known to inhibit terminal differentiation of cardiac progenitors and it also modulates ROCK activity and expression. 26, 36, 37 The inhibition of late stages of cardiomyogenesis by Wnt3a primarily has been attributed to the canonical/β-catenin pathway, whereas noncanonical Wnt signaling is usually considered supportive for terminal differentiation. 19, 25, 26 Although the activation of ROCK generally is associated with the noncanonical/planar cell polarity pathway, the Rho/ROCK pathway is activated by Wnt3a 37,38 and is required for subsequent β-catenin-dependent gene activation. 36 We tested whether the Wnt inhibitor Dkk1 could modulate ROCKmediated phosphorylation of Mypt1 at T853, which, in addition to being relevant to our study, is a reliable measure of ROCK activity. 39 Although a previous study reported that Dkk1 does not modulate Rho activation in myeloma cells, 40 we found that in our system, Dkk1 treatment resulted in a reproducible decrease (≈20%) in the level of phosphorylated Mypt1 relative to total Mypt1 (Figure 5A and 5B) . Therefore, blocking Wnt signaling results in decreased ROCK activity and Mypt1 phosphorylation.
We next sought to establish a link between Wnt signaling and nuclear exclusion of Nkx2.5. We cotransfected Flag-Nkx2.5 with MP and analyzed the subcellular distribution of Nkx2.5 in the presence and absence of Dkk1. By immunofluorescence analysis, treatment with Dkk1 significantly inhibited the MPdependent nuclear exclusion of Nkx2.5 when compared with vehicle ( Figure 5C and 5D) . These data identify a correlation between the Wnt-regulated level of Mypt1 phosphorylation and the MP-dependent nuclear exclusion of Nkx2.5.
Wnt3a Treatment of Differentiating mESCs Excludes Nkx2.5 From the Nucleus and Inhibits Cardiomyogenesis
Because activation of Wnt signaling at late stages of mESC cardiomyogenesis is known to be inhibitory, 25, 26 we sought to determine whether this involves nuclear exclusion of Nkx2.5. Differentiating mESCs were treated with Wnt3a or vehicle control from days 4 to 7, and the effects on cardiomyogenesis were examined by gene expression analysis and immunofluorescence. Treatment of differentiating mESCs with Wnt3a resulted in a reduced number of Mlc2v +ve cardiomyocytes ( Figure 6A and 6B ). This was accompanied by a significant reduction in transcript levels of cardiomyogenic markers, including Nkx2.5, Mlc2v, connexin 40, atrial natriuretic factor, and myosin heavy chain 6 ( Figure  6C) . Notably, the expression of GATA4 was not significantly affected by Wnt3a treatment (Figure 6C ). The transcript levels of Nkx2.5 were strongly downregulated in response to Wnt3a treatment, which is consistent with recent evidence that Wnt signaling modulates Nkx2.5 expression. 41 To determine whether reduced cardiomyogenesis correlated with changes in MP phosphorylation, we examined levels of pMypt1T853 in Wnt3a and vehicle-treated cultures. Consistent with the results of Dkk1 treatment, Wnt3a treatment resulted in increased levels of pMypt1T853 ( Figure 6D ). We next analyzed the subcellular distribution of endogenous Nkx2.5 in Wnt3a and vehicle-treated cultures. In vehicle-treated mESCs, Nkx2.5 was primarily localized to the nucleus, with only a small number (≈2%) of cells displaying a perinuclear pattern ( Figure 6E and 6F) . In Wnt3a-treated cells, however, the fraction of cells in which endogenous Nkx2.5 was excluded from the nucleus increased significantly to ≈8% (Figure 6E and 6F). To determine the differentiation status of these cells, we colabeled them with antibodies against Mlc2v ( Figure 6F ). Whereas cells that exhibited a nuclear pattern of Nkx2.5 expression differentiated into Mlc2v +ve cardiomyocytes, we did not observe any Mlc2v +ve cardiomyocytes in which Nkx2.5 was excluded from the nucleus, suggesting that this phenomenon is associated with a failure to undergo terminal differentiation. As in our transient transfection experiments, excluded Nkx2.5 colocalized with pMypt1T853 ( Figure 6G ). Therefore, endogenous Nkx2.5 is excluded from the nucleus in response to Wnt3a treatment of differentiating mESCs, and this exclusion correlates with a failure to differentiate. 
Knockdown of Mypt1 Results in Enhanced Cardiac Gene Expression and Rescue of Wnt3a-Mediated Inhibition of Cardiomyogenesis
We next sought to determine whether the endogenous Nkx2.5 and MP proteins interacted during mESC differentiation. Nkx2.5 was immunoprecipitated from differentiating mESCs using anti-Nkx2.5 antibodies and nonspecific IgG; Nkx2.5 and Mypt1 proteins were visualized by Western blotting. Consistent with our previous analyses, Mypt1 was detected in Nkx2.5-immunoprecipitated fractions, indicating that the endogenous proteins interact during mESC differentiation ( Figure 7A ). Interestingly, the major Nkx2.5 band identified in the immunoprecipitation migrated with the 50 kDa marker, which is significantly larger than the predicted molecular weight of 34 kDa. This has been observed in other systems 42, 43 and likely represents posttranslational modification of Nkx2.5. Given that the proteins form a complex during mESC differentiation, we next sought to determine whether the loss of MP would enhance mESC differentiation into cardiomyocytes. We infected mESCs with lentiviruses expressing 3 shRNAs targeted to Mypt1, 2 of which (sh152 and sh346) produced stable lines exhibiting significant knockdown of Mypt1 expression (>60%) with a concomitant decrease in pMypt1T853 levels (≈50%) ( Figure 7B and 7C) . The 2 knockdown lines (termed shMypt1) were differentiated, and the level of cardiac gene expression was compared with a stable cell line expressing a nontarget shRNAmir control. Consistent with an inhibitory role for Mypt1, shMypt1 cells expressed significantly higher levels of Nkx2.5, Mlc2v, and myosin heavy chain 6 relative to control ( Figure 7D ).
To examine whether Mypt1 is required for inhibition of cardiomyogenesis by Wnt3a, we treated differentiating shMypt1 and control cells with Wnt3a and assessed the extent of cardiomyogenic differentiation by gene expression analysis and immunofluorescence. As in our previous experiments, the expression levels of Nkx2.5, myosin heavy chain 6, and connexin 40 in control cells ( Figure 7E ) were reduced on treatment with Wnt3a. In shMypt1 cells, however, there was no significant difference between vehicle and Wnt3a treatments, indicating that these cells are refractory to Wnt3a-mediated inhibition ( Figure 7E ). We also observed an alleviation of Wnt3a inhibition by quantitative analysis of the number of myosin heavy chain-positive cells in control and shMypt1 cultures ( Figure  7F and 7G) . These data are consistent with our model and support a mechanism in which Mypt1 is required for Wnt3amediated inhibition of cardiomyogenesis in mESCs.
Discussion
Nkx2.5 is among the earliest genes expressed during cardiomyogenesis, and it regulates many target genes that are essential for heart development. 7, 8 Despite this, little is known about how Nkx2.5 function is regulated. We have shown that PP1β and Mypt1, subunits of the MP complex, are novel interacting partners of Nkx2.5 (Online Table I and Figure 1A ). Nkx2.5 interacted specifically with the phosphorylated form of MP, resulting in nuclear exclusion of Nkx2.5 and a decrease in its transcriptional activity, in a mechanism dependent on a newly identified Mypt1 NES (Figures 1-4 ). This interaction was modulated by the Wnt inhibitor Dkk1, which reduced Mypt1 phosphorylation ( Figure 5 ). Consistent with this, treatment of differentiating mESCs with Wnt3a resulted in enhanced nuclear exclusion of endogenous Nkx2.5, associated with downregulation of cardiac gene expression and inhibition of cardiomyogenesis ( Figure 6 ). Finally, knockdown of Mypt1 enhanced overall cardiomyogenesis and rescued Wnt3a-mediated inhibition (Figure 7) . Taken together, these findings suggest a model whereby Wnt3a activates ROCK, which in turn phosphorylates MP, stimulating its translocation to the nucleus. MP then engages Nkx2.5, and the complex is exported to the perinuclear region via the chromosome region maintenance 1 pathway. These findings are summarized in a model shown in Figure 8 .
It previously has been reported that MP interacts with and dephosphorylates histone deacetylase 7, causing it to translocate to the nucleus. 44 We have shown that Nkx2.5 interacts with a form of the MP complex containing phosphorylated Mypt1. This phosphorylation event has profound inhibitory effects (>100-fold decrease in activity) on the phosphatase activity of the PP1β subunit, which result from docking of the phosphorylated T853 residue within its active site. 33, 34 Therefore, it is unlikely that the regulation of the subcellular localization of Nkx2.5 is dependent on dephosphorylation by MP, although our data cannot rule out this possibility. We also have not ruled out that Nkx2.5 phosphorylation via other mechanisms may play a role in its subcellular distribution. However, we have shown that modulating ROCK activity can alter the subcellular redistribution of Nkx2.5 in response to coexpression with MP by regulating the levels of pMypt1T853. Notably, inhibition of ROCK activity significantly enhances survival of human embryonic stem cell-derived cardiomyocytes after dissociation of EBs. 45 Given that Nkx2.5 protects cardiomyocytes from stress-induced cell death, it is tempting to speculate that changes in the subcellular distribution of Nkx2.5 may contribute to the protective effects conferred by ROCK inhibition. 46 Wnt3a is known to inhibit terminal cardiac differentiation of mESCs, although mechanistic insight into this regulation is not fully developed. 26 We have shown in this study that treatment of differentiating mESCs with Wnt3a results in exclusion of Nkx2.5 from the nucleus, which is accompanied by reduced cardiomyogenic differentiation. Consistent with this, knockdown of Mypt1 in mESCs results in rescue of Wnt3a-mediated inhibition of cardiomyogenesis. This represents a novel mechanism whereby Wnt3a signaling inhibits differentiation of cardiac progenitors. Although ROCK traditionally has been associated with the Wnt/planar cell polarity pathway, it is activated by Wnt3a 37, 38 and is required for β-catenin function. 36 We have shown that Dkk1 can partially block ROCK-mediated phosphorylation of Mypt1, supporting a possible link between ROCK activation and signaling downstream of the Lrp5/6 receptor. Although our data are consistent with recent work indicating that ROCK is involved in Wnt/β-catenin signaling, 36 others have shown that Dkk1 cannot inhibit Wnt activation of rho in myeloma cells. 40 This difference may be representative of both the complexity of Wnt signaling and dissimilarity between the biological systems. Alternatively, it has been shown that Wnt3a treatment of mesenchymal stem cells results in increased expression of the ROCK2 isoform. 36 Therefore, it is possible that the reduction in ROCK activity on treatment with Dkk1 is reflective of reduced gene expression levels rather than direct inhibition of ROCK activation by rhoA. The extent of inhibition of Nkx2.5 exclusion by Dkk1 (≈40%) was stronger than expected based on the changes in Mypt1 phosphorylation levels ( Figure 5 ). This may be indicative of a threshold effect whereby pMypt1T853 must accumulate within the nucleus at high levels for exclusion of MP/Nkx2.5 to be initiated or of additional roles for Dkk1 in this process.
Previous studies have shown that Nkx2.5 activity is not essential for cardiac differentiation of mESCs. 9 Therefore, whereas promoting nuclear exclusion of Nkx2.5 may represent at least part of the anticardiomyogenic effects exerted by Wnt3a, additional mechanisms are likely at play, such as transcriptional regulation of Nkx2.5 and other important cardiomyogenic factors. 41 It is also possible that nuclear exclusion of Nkx2.5 may contribute to enhanced protein turnover. Furthermore, given that knockdown of Mypt1 was able to fully rescue Wnt3a-mediated inhibition, it is possible that MP is involved in additional inhibitory pathways mediated by Wnt. Whether nuclear exclusion also can inhibit the repressive function of Nkx2.5 remains to be determined. 12 A recent study 47 showed that treatment of EBs with Wnt3a results in activation of a Wnt-responsive promoter throughout the EB and that this was delayed by treatment with Dkk1. Visualization of endogenous Wnt signaling using a reporter in EBs revealed that it is initially localized to distinct regions of the EB and is self-perpetuating until it encompasses the whole EB. 47 We consistently observed exclusion of Nkx2.5 in localized patches ( Figure 7F ). Perhaps the regions that fail In response to Wnt3a signaling, myc-myosin phosphatase targeting subunit 1 (Mypt1) is phosphorylated at Thr853 by ROCK, causing MP to translocate into the nucleus, where it can engage Nkx2.5 and form a complex, which is then exported from the nucleus in a chromosome region maintenance 1 (Crm1)-dependent pathway.
to become Wnt-responsive are those that express endogenous antagonistic signaling molecules, such as Dkk1, that override Wnt3a and block exclusion of Nkx2.5, resulting in patches of excluded and nuclear Nkx2.5. Although we have shown that Wnt3a inhibition requires Mypt1, given that most cells retain Nkx2.5 in the nucleus even after treatment with Wnt3a, it is also likely that other mechanisms contribute to this pathway.
We have recently shown that myosin light chain kinase enhances skeletal myogenesis by phosphorylating MEF2C. 48 When considered together with the model described here, as well as with work performed by others, it appears that modulating the balance of myosin phosphorylation represents only 1 aspect of a more diverse role played by myosin light chain kinase/MP. 44 In summary, we have found that interaction with MP regulates the subcellular distribution of Nkx2.5 downstream of Wnt3a and consequently modulates cardiomyogenesis in stem cells. These findings provide novel mechanistic insight into Wnt-mediated modulation of the cardiac cell fate in embryonic stem cells.
